SRTA
BEARISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Trades near book value, but lacks earnings to support a traditional valuation.
- Price/Book ratio of 1.09 is relatively low
- No P/E or Graham Number due to lack of consistent earnings
Growth is purely top-line; failure to convert revenue to operating profit is a major concern.
- Strong YoY revenue growth (83.5%)
- Positive Q/Q revenue momentum (22.87%)
- Negative YoY EPS growth (-20%)
Historical earnings track record is poor with significant negative surprises.
- Strong 1-year price performance
- Consistent failure to meet earnings estimates
- Long-term 5Y change is negative (-54.4%)
Despite high liquidity, the F-Score indicates a total lack of positive fundamental trends.
- Low debt
- High current ratio
- Piotroski F-Score of 0/9
Non-dividend paying growth/speculative stock.
- No dividend paid
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for SRTA and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
SRTA
Strata Critical Medical, Inc.
Primary
|
-54.4% | +64.4% | +74.4% | -8.4% | +6.0% | +13.1% |
|
ENTA
Enanta Pharmaceuticals, Inc.
Peer
|
-71.8% | -64.9% | +208.7% | +21.9% | -0.9% | +6.2% |
|
KIDS
OrthoPediatrics Corp.
Peer
|
-67.6% | -67.3% | -25.3% | -2.0% | -10.3% | -0.6% |
|
AKBA
Akebia Therapeutics, Inc.
Peer
|
-59.4% | +113.8% | -13.6% | -50.5% | -5.8% | +15.0% |
|
NRC
National Research Corporation
Peer
|
-58.9% | -57.9% | +63.5% | +50.6% | -1.2% | 0.0% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
SRTA
Strata Critical Medical, Inc.
|
BEARISH | $397.54M | - | -8.0% | 21.0% | $4.57 | |
|
ENTA
Enanta Pharmaceuticals, Inc.
|
BEARISH | $399.6M | - | -60.0% | -106.8% | $13.77 | Compare |
|
KIDS
OrthoPediatrics Corp.
|
BEARISH | $403.7M | - | -11.3% | -16.8% | $15.97 | Compare |
|
AKBA
Akebia Therapeutics, Inc.
|
BEARISH | $391.1M | - | -% | -2.3% | $1.46 | Compare |
|
NRC
National Research Corporation
|
BEARISH | $387.6M | 34.08 | 51.2% | 8.4% | $17.04 | Compare |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-16 | WUNSCH SCOTT M | Officer | Stock Award | 18,067 | - |
| 2026-02-24 | COHEN AMIR | Officer | Stock Award | 64,191 | - |
| 2026-02-24 | WUNSCH SCOTT M | Officer | Stock Award | 51,353 | - |
| 2026-01-02 | TOMKIEL MELISSA M. | Chief Executive Officer | Option Exercise | 276,960 | $49,853 |
| 2025-12-09 | HEYBURN WILLIAM A | Chief Executive Officer | Purchase | 17,000 | $76,044 |
| 2025-12-05 | LAUCK ANDREW | Director | Purchase | 5,000 | $21,825 |
| 2025-12-02 | WUNSCH SCOTT M | Officer | Stock Award | 13,395 | - |
| 2025-12-02 | COOK WILLIAM L III | Director | Stock Award | 53,233 | - |
| 2025-12-02 | VERDETTO LOUIS R | Officer | Stock Award | 63,918 | - |
| 2025-11-20 | LOVE REGINALD LAMONTE | Director | Sale | 11,000 | $48,070 |
| 2025-11-19 | LOVE REGINALD LAMONTE | Director | Sale | 11,000 | $47,434 |
| 2025-11-07 | TOMKIEL MELISSA M. | Chief Executive Officer | Option Exercise | 27,778 | $5,000 |
| 2025-10-31 | HEYBURN WILLIAM A | Chief Executive Officer | Stock Award | 181,072 | - |
| 2025-10-31 | TOMKIEL MELISSA M. | Chief Executive Officer | Stock Award | 208,929 | - |
| 2025-10-31 | COHEN AMIR | Officer | Stock Award | 41,786 | - |
SEC Filings
Recent regulatory filings from the SEC EDGAR database
SRTA filed its 10-K on March 3, 2026, which includes comprehensive disclosures regarding its business operations and financial condition. The filing contains dedicated sections for Management’s Discussion and Analysis and Risk Factors to outline the company's financial performance and potential operational threats.
Wall Street Analysts
Professional analyst ratings and price targets
Past News Coverage
Recent headlines mentioning SRTA from our newsroom.